AlphaherpesvirusFeline herpesvirus 1Modified-live vaccinesTrigeminal ganglion latencyUpper respiratory tract disease
Figures from the paper
Abstract (AI)
Feline herpesvirus (FHV-1; felid herpesvirus 1 (FeHV-1)) is an alphaherpesvirus of cats closely related to canine herpesvirus-1 and phocine herpesvirus-1. There is only one serotype of the virus and it is relatively homogenous genetically. FeHV-1 is an important cause of acute upper respiratory tract and ocular disease in cats. In addition, its role in more chronic ocular disease and skin lesions is increasingly being recognised. Epidemiologically, FeHV-1 behaves as a typical alphaherpesvirus whereby clinically recovered cats become latently infected carriers which undergo periodic episodes of virus reactivation, particularly after a stress. The primary site of latency is the trigeminal ganglion. Conventional inactivated and modified-live vaccines are available and protect reasonably well against disease but not infection, although viral shedding may be reduced. Genetically engineered vaccines have also been developed, both for FeHV-1 and as vector vaccines for other pathogens, but none is as yet marketed.
Key Findings
1
Clinically recovered cats remain latently infected carriers, with stress-associated reactivation occurring primarily from the trigeminal ganglion.
2
Conventional inactivated and modified-live vaccines reduce disease effectively but do not reliably prevent infection, although they may reduce viral shedding.
3
FeHV-1 is a major cause of acute feline upper respiratory and ocular disease, and is increasingly linked to chronic ocular disease and skin lesions.
4
Feline herpesvirus 1 is a genetically homogeneous alphaherpesvirus with a single known serotype infecting cats.
5
Genetically engineered FeHV-1 vaccines and FeHV-1-based vector vaccines have been developed, but none is currently marketed.
Research Object
Feline herpesvirus 1 (FeHV-1), an alphaherpesvirus infecting cats
Research Subject
Its disease manifestations, latency and reactivation epidemiology, and vaccine-mediated protection
Publication Details
Publication Date
2007-02-12
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest